Caredx Stock News

October was a good month in the markets. It won't be easy to find stocks to buy on the dip.

MetLife Investment Management LLC trimmed its holdings in CareDx, Inc (NASDAQ:CDNA) by 6.6% during the second quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 17,647 shares of the companys stock after selling 1,254 shares during the quarter. MetLife Investment Management LLCs holdings in CareDx were worth []

Amalgamated Bank increased its stake in CareDx, Inc (NASDAQ:CDNA) by 32.2% during the second quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 9,450 shares of the companys stock after acquiring an additional 2,304 shares during the quarter. Amalgamated Banks holdings in CareDx were worth $865,000 at the []

Should you follow the internet's favorite stock picker into this tumbling diagnostics stock?

CareDx Inc (NASDAQ: CDNA) reported Q3 revenues rose 42% Y/Y to $75.6 million, beating the consensus of $74.05 million.  The increase was driven mainly by a 46% increase in testing service revenues

Third-quarter 2021 results were terrific, but the disclosure of two federal investigations isn't sitting well with investors.

CareDx, Inc. (CDNA) CEO Reg Seeto on Q3 2021 Results - Earnings Call Transcript

CareDx (CDNA) delivered earnings and revenue surprises of 133.33% and 1.82%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?

SOUTH SAN FRANCISCO, Calif., Oct. 14, 2021 (GLOBE NEWSWIRE) -- CareDx, Inc. (Nasdaq: CDNA), a leading precision medicine company focused on the discovery, development, and commercialization of clinica

AlloSure Significantly Improves Management of High-Risk Lung Transplant Patients AlloSure Significantly Improves Management of High-Risk Lung Transplant Patients

Multicenter Study Validates AlloMap and Demonstrates the Complementary Value with AlloSure for Detecting Rejection Multicenter Study Validates AlloMap and Demonstrates the Complementary Value with All

False Advertising Lawsuit Against Natera is Set to Go to Trial

AlloSeq to be featured in 8 scientific abstracts at ASHI conference AlloSeq to be featured in 8 scientific abstracts at ASHI conference

Which subset of the COVID-19 healthcare market will outperform over the next year?

CareDx announces the launch of AlloSeq cfDNA Research Service and demonstrates global leadership at ESOT with six abstracts and a symposium CareDx announces the launch of AlloSeq cfDNA Research Servic